

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- In the Headlines: Could “flooding the zone” drown NIH and cancer centers?
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- In the Headlines: What are Jay Bhattacharya’s plans for NIH?
- The University of Rochester Wilmot Cancer Institute earns NCI Cancer Center designation